Creative Medical Technology Holdings, Inc. (CELZ) financial statements (2021 and earlier)

Company profile

Business Address 2017 W PEORIA AVENUE
PHOENIX, AZ 85029
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments158204419304173101102
Cash and cash equivalents158204419304173101102
Receivables25101014510
Total current assets:183205420314187105112
Noncurrent Assets
Intangible assets, net (including goodwill)148153158164169174179
Intangible assets, net (excluding goodwill)148153158164169174179
Total noncurrent assets:148153158164169174179
TOTAL ASSETS:330358578477356279291
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities389412412353272313259
Accounts payable324320343332243273233
Accrued liabilities65917022304025
Debt8961,0701,079682339365384
Derivative instruments and hedges, liabilities2,5441,3852,5273,2276,8189,9297,046
Due to related parties11111111111111
Other undisclosed current liabilities53118153198269254522
Total current liabilities:3,8932,9954,1834,4727,71010,8718,221
Noncurrent Liabilities
Liabilities, other than long-term debt      4
Accounts payable and accrued liabilities      4
Total noncurrent liabilities:      4
Total liabilities:3,8932,9954,1834,4727,71010,8718,225
Stockholders' equity
Stockholders' equity attributable to parent, including:(3,563)(2,637)(3,605)(3,995)(7,354)(10,595)(7,934)
Common stock2,1081,1881,007903784677400
Additional paid in capital14,69914,13913,26312,18110,8756,1722,678
Accumulated deficit(20,373)(17,967)(17,879)(17,081)(19,016)(17,445)(11,012)
Other undisclosed stockholders' equity attributable to parent33333  
Other undisclosed stockholders' equity     3 
Total stockholders' equity:(3,563)(2,637)(3,605)(3,995)(7,354)(10,592)(7,934)
TOTAL LIABILITIES AND EQUITY:330358578477356279291

Income statement (P&L) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Revenues5862515852510
Cost of revenue(8)(19)(14)(29)(36)(3)(2)
Gross profit:504237291627
Operating expenses(323)(318)(287)(349)(291)(317)(211)
Operating loss:(273)(275)(251)(320)(275)(315)(204)
Nonoperating income (expense)(2,133)187(547)2,255(1,296)(6,118)(7,382)
Interest and debt expense11(504)(357)33970651(154)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   70(70)(651)154
Income (loss) from continuing operations before equity method investments, income taxes:(2,395)(592)(1,155)2,343(1,571)(6,432)(7,587)
Other undisclosed income (loss) from continuing operations before income taxes(11)504357(408)   
Net income (loss) available to common stockholders, diluted:(2,406)(88)(797)1,934(1,571)(6,432)(7,587)

Comprehensive Income ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net income (loss):(2,406)(88)(797)1,934(1,571)(6,432)(7,587)
Comprehensive income (loss), net of tax, attributable to parent:(2,406)(88)(797)1,934(1,571)(6,432)(7,587)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: